Loading...
•
Jun 30, 2023
Aquestive Q2 2023 Earnings Report
Aquestive reported a decrease in net loss driven by increased revenue, decreased SG&A and R&D expenses, and reduced non-cash interest expense.
Key Takeaways
Aquestive Therapeutics reported second quarter 2023 financial results with a total revenue of $13.2 million and a net loss of $5.8 million, marking a significant decrease compared to the previous year's net loss of $16.3 million. Excluding the impact of prior year proprietary sales of Sympazan, total revenues increased from $10.7 million in the second quarter 2022 to $13.2 million in the second quarter 2023, driven by higher revenue from out-licensed products. The company is advancing its product pipeline, including Anaphylm and Libervant, and has updated its full-year 2023 financial guidance.
Submitted proposed pivotal trial protocol for Anaphylm to the FDA.
Submitted an NDA to the FDA for Libervant for patients between two and five years of age.
Reported 24% year-over-year growth in quarterly revenue adjusted for the out-license of Sympazan.
Raised full year 2023 revenue and improved non-GAAP adjusted EBITDA loss guidance.
Forward Guidance
Aquestive is updating its full-year 2023 financial guidance based on second quarter 2023 results and updated outlook for the remainder of 2023.
Positive Outlook
- Total revenue (in millions): $44 to $48
- Non-GAAP adjusted EBITDA loss (in millions): $19 to $22
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...